LTR Executes Definitive U.S. Commercial Agreement with Shed
Filed with ASX · · 5 pages · English
Summary by 6ix AI
LTR Pharma Limited has executed a definitive commercial agreement with Shed, a U.S. telehealth platform, to facilitate the U.S. commercialization of ROXUS. This agreement converts a previously announced term sheet into a comprehensive framework for collaboration on marketing and operational activities. Shed has committed to delivering a significant volume of ROXUS units within the first year following the commercial launch, marking a key milestone in LTR Pharma's strategy. Both companies will now focus on completing implementation activities ahead of the planned launch of ROXUS in the U.S.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from LTR Pharma
- Response to ASX Aware Letter
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
- LTR Secures First U.S. Commercial Agreement for ROXUS
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- SPONTAN Phase II data show rapid onset, support FDA pathway
Later from LTR Pharma
- LTR Executes U.S. Commercial Agreement with Strive
- Quarterly Activities/Appendix 4C Cash Flow Report
- SPONTAN Real-World Study Reports 93% Response
- Appendix 4E and Annual Report to Shareholders
- Appendix 4G and Corporate Governance Statement
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma